IMR-261

N/A

Report date: 2025/11/17 12:03:57
NME

Base Information

Drug NameIMR-261
Drug Alias Name10‐nitro‐9(E)‐octadec‐9‐enoic acidE-10-NO2-18:1CXA-10IMR-261
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHeat-shock protein stimulantsNuclear factor NF-kappa-B complex inhibitorsToll like receptor 4 inhibitors +[5] 
TargetsNuclear factor erythroid 2-related factor 2Heat-shock proteinNuclear factor NF-kappa-B complex +[5] 
Therapy Area/IndicationsObesityAcute Kidney InjuryGlomerulosclerosis, Focal Segmental +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesComplexa Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Colorado Denver
Inactive CompaniesComplexa Inc
Active IndicationsObesityAsthma
Inactive IndicationsAcute Kidney InjuryGlomerulosclerosis, Focal SegmentalPhenylketonurias +[4] 

Other Information

ATC CodeN/A
Related LinksN/A